AstraZeneca closes India R&D shop

Share this article:

AstraZeneca is laying off 168 pharmaceutical employees at the Avishkar R&D site in Bangalore, India. The company said in a statement that the move is in line with its shift to focus on three core areas—oncology; cardiovascular and metabolic; and respiratory, inflammation and autoimmunity.

The Avishkar operation was focused on conditions including TB, malaria and neglected tropical diseases. AstraZeneca will continue to develop Phase-II TB medication AZD5847. The company said it will continue to make its compound library available to open-innovation partnerships.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters